<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JACC Adv</journal-id><journal-id journal-id-type="iso-abbrev">JACC Adv</journal-id><journal-title-group><journal-title>JACC: Advances</journal-title></journal-title-group><issn pub-type="epub">2772-963X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40286360</article-id><article-id pub-id-type="pmc">PMC12101536</article-id><article-id pub-id-type="pii">S2772-963X(25)00111-5</article-id><article-id pub-id-type="doi">10.1016/j.jacadv.2025.101694</article-id><article-id pub-id-type="publisher-id">101694</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Prevalence, Risk Factors, and Prognosis for Fontan-Associated Liver Disease</article-title><subtitle>A Systematic Review and Exploratory Meta-Analysis</subtitle></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Cao</surname><given-names>Jacob Y.</given-names></name><degrees>MSc, MBBS</degrees><email>jacob.cao@sydney.edu.au</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Wales</surname><given-names>Kathyrn M.</given-names></name><degrees>BSc, MBBS</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>d&#x02019;Udekem</surname><given-names>Yves</given-names></name><degrees>MBBS, PhD</degrees><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Celermajer</surname><given-names>David S.</given-names></name><degrees>MBBS, PhD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Cordina</surname><given-names>Rachael</given-names></name><degrees>MBBS, PhD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Majumdar</surname><given-names>Avik</given-names></name><degrees>MBBS, PhD</degrees><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><aff id="aff1"><label>a</label>Department of Cardiology, St. Vincent&#x02019;s Hospital, Sydney, Australia</aff><aff id="aff2"><label>b</label>Sydney Medical School, University of Sydney, Sydney, Australia</aff><aff id="aff3"><label>c</label>Department of Cardiology, Liverpool Hospital, Sydney, Australia</aff><aff id="aff4"><label>d</label>Division of Cardiac Surgery, Children&#x02019;s National Hospital, Washington, District of Columbia, USA</aff><aff id="aff5"><label>e</label>The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA</aff><aff id="aff6"><label>f</label>Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia</aff><aff id="aff7"><label>g</label>Victorian Liver Transplant Unit, Austin Health, Melbourne, Australia</aff><aff id="aff8"><label>h</label>Melbourne Medical School, University of Melbourne, Melbourne, Australia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Address for correspondence:</bold> Dr Jacob Y. Cao, Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia 2050. <email>jacob.cao@sydney.edu.au</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>4</month><year>2025</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>101694</elocation-id><history><date date-type="received"><day>17</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Patients with Fontan circulation are at risk of progressive liver disease, but the prevalence and risk factors for Fontan-associated liver disease (FALD) remain unclear.</p></sec><sec><title>Objectives</title><p>The aim of the study was to review unbiased data on FALD prevalence, diagnostic methods, risk factors, and prognostic significance, and to undertake exploratory meta-analysis on available data.</p></sec><sec><title>Methods</title><p>This systematic review included studies with unselected FALD screening. Outcomes were imaging or biopsy-proven cirrhosis, advanced fibrosis, portal hypertension, and hepatocellular carcinoma. Exploratory meta-analysis was performed, as well as subgroup analyses and meta-regression to explore contributors towards outcome heterogeneity.</p></sec><sec><title>Results</title><p>Thirty-seven studies comprising 5,701 patients were included, with a median of 17&#x000a0;years of follow-up post-Fontan completion. All estimates of FALD were highly heterogeneous, reflecting variable patient factors and institutional practices. Cirrhosis was diagnosed in 21% of patients, but ranged from 0% to 76%. Advanced fibrosis without cirrhosis was noted in 30%, portal hypertension in 17%, and hepatocellular carcinoma in 2%, also with significant heterogeneity. Subgroup analysis and meta-regression highlighted several factors that contributed to such heterogeneity. It was found that cirrhosis was less commonly diagnosed by biopsy than by imaging (10% vs 26%). Other risk factors for cirrhosis included years post-Fontan completion, atriopulmonary Fontan, moderate or greater ventricular dysfunction, and higher pulmonary capillary wedge pressure. Qualitative synthesis noted FALD to be associated with elevated risk of cardiovascular and all-cause mortality.</p></sec><sec><title>Conclusions</title><p>Liver disease is common post-Fontan completion, though prevalence varies widely. Several risk factors should guide patient screening. A universal, prognostically meaningful FALD definition is needed to advance research and clinical care.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Central Illustration</title><fig id="undfig1" position="anchor"><graphic xlink:href="ga1"/></fig></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>cirrhosis</kwd><kwd>hepatocellular carcinoma</kwd><kwd>single ventricle</kwd></kwd-group></article-meta><def-list><title>Abbreviations and Acronyms</title><def-item><term id="kwrd0030">AP</term><def><p>atriopulmonary</p></def></def-item><def-item><term id="kwrd0040">CVP</term><def><p>central venous pressure</p></def></def-item><def-item><term id="kwrd0050">FALD</term><def><p>Fontan-associated liver disease</p></def></def-item><def-item><term id="kwrd0060">HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term id="kwrd0070">MELD-XI</term><def><p>Model for End-stage Liver Disease excluding INR</p></def></def-item><def-item><term id="kwrd0080">PCWP</term><def><p>pulmonary capillary wedge pressure</p></def></def-item></def-list></front><body><p id="p0010">The Fontan circulation, also known as a univentricular circulation, is the result of several staged operations that redirect systemic venous blood flow into the pulmonary arteries without transiting through a functioning subpulmonic ventricle. While this circulation has significantly improved survival in patients with complex congenital heart disease<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>, cardiac and extra-cardiac complications continue to accrue over the lifetime of these patients due to their unique physiology. By necessity, systemic venous pressure is persistently elevated in this situation, and cardiac output is often low. These factors may have implications for the liver. Fontan-associated liver disease (FALD) describes a wide spectrum of progressive liver injury that is seen in these individuals.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Despite being first described in the 1980s and subsequent ubiquitous use of the term in published literature, there remains no unifying definition.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> This likely stems from a combination of poor understanding of pathophysiology, biased prevalence data, unvalidated diagnostic methods, and unclear prognostic significance of FALD. Similar issues were highlighted in a 2017 expert statement, describing these as major barriers toward effective screening and treatment strategies.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p><p id="p0015">Point prevalence estimates of FALD vary widely in the literature, in part due to selection bias of the cohort being studied.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Since liver follow-up protocols differ between centers, so too does the pretest probability of patients screened for FALD. A range of diagnostic methods with different thresholds for FALD has also been described, which further exacerbates the highly variable prevalence estimates. Diagnostic tests have included serological panels, imaging parameters, or histopathology, and while validated in the other causes of cirrhosis, their value in FALD is unclear. To date, there has been no comprehensive review of the existing FALD literature to qualitatively and quantitatively summarize what is known, and in doing so, to highlight the current issues that should be addressed in forthcoming research. Therefore, the aim of the current systematic review is to present an unbiased overview of the prevalence, diagnostic methods, risk factors, and prognostic significance of FALD. An exploratory meta-analysis was also performed to evaluate factors that underpin the highly heterogenous prevalence estimates in the literature and that may be useful in individual patient risk stratification.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Literature search strategy</title><p id="p0020">A systematic review and meta-analysis was performed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Electronic searches using Medline, PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were undertaken to include all relevant studies up to September 2023. A search strategy was devised to maximize sensitivity (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Appendix</xref>), combining synonyms and variations of &#x0201c;Fontan OR total cavopulmonary anastomosis&#x0201d; AND &#x0201c;cirrhosis OR portal hypertension OR hepatic fibrosis OR hepatocellular carcinoma.&#x0201d; The search was limited to human subjects only. No limit was set on language. Additionally, reference lists of retrieved articles and reviews were examined for further studies. European, American, and Australian trial registries were also searched for relevant studies (www.anzctr.org.au; www.clinicaltrials.gov; www.clinicaltrialsregister.eu). Where studies were from the same center that reported on the same outcomes, the one with the largest cohort size was used. Where a multicenter study was included, any other study from one of the participating centers was excluded. No ethics committee approval was required for the current systematic review.</p></sec><sec id="sec1.2"><title>Selection criteria and data extraction</title><p id="p0025">To be included for statistical synthesis, individual studies had to meet the following criteria: 1) inclusion of patients with Fontan circulation; 2) report at least one clinical outcome of interest as described below. Studies were excluded if: 1) liver screening was selectively undertaken for those with pre-existing or suspected liver disease; 2) there were less than 5 patients; and 3) containing data from registries without specifying participating centers resulting in the risk of duplication bias. Where several studies arose from the same research group, only the one with the largest cohort was included. Duplicate studies from the same group were only included if they reported on mutually exclusive outcomes (eg, cirrhosis and portal hypertension).</p><p id="p0030">Nonselective methods of liver screening included 1) consecutive recruitment; 2) screening as part of institutional protocol; and 3) screening patients based on criteria that are unlikely related to FALD risk (eg, geographic location). Examples of selective screening include evaluating only patients with suspected liver disease based on clinical or biochemical abnormalities, preheart or liver transplant patients, or patients with failing Fontan circuits. Where the selection protocol was not specified, the studies were included, but subsequent sensitivity analyses were done to evaluate their effect on the outcomes. Certain studies specified exclusion of other common causes of liver disease (eg, viral hepatitis and significant alcohol intake), but given that these are uncommon in a young Fontan population, studies that did not specify these exclusions were included for the current meta-analysis.</p><p id="p0035">Title and abstract screening and data extraction were independently performed by 2 investigators (J.Y.C. and K.M.W.). Disagreements were resolved by a third author (R.C.). The primary outcome of interest was cirrhosis, and secondary outcomes were advanced fibrosis without cirrhosis, portal hypertension and hepatocellular carcinoma (HCC). There is significant variation in definition of each outcome (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Table&#x000a0;1</xref>). We excluded studies using only serological markers for diagnoses given different thresholds between studies as well as a lack of strong evidence for their use in FALD.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Imaging and biopsy parameters used for diagnoses also varied between investigators but were reviewed by a senior hepatologist with experience in FALD (A.M.) for inclusion. Ultimately, all studies using imaging or biopsy were included given the lack of established diagnostic criteria and to maximize the representativeness of the systematic review. Additional baseline variables relating to study characteristics, patient demographics, cardiac function, and hemodynamics were extracted for post hoc subgroup analyses and meta-regression. Where actuarial incidence was not reported at a specific time point, data were extracted from available Kaplan-Meier curves using Plot Digitizer (https://plotdigitizer.com). For example, although Inuzuka et&#x000a0;al<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> reported 67 cases of cirrhosis at a median of 10.3&#x000a0;years of follow-up, it was unclear whether this was from Fontan completion or from the first contact with the study investigators pre-Fontan completion. As such, the presented Kaplan-Meier curves of post-Fontan cirrhosis prevalence were used instead to extract data at 15&#x000a0;years, at which point the study had a third of the original cohort still being followed up.</p><p id="p0040">Exploratory statistical synthesis was not performed for FALD prognosis and management due to highly variable definitions and outcomes. Rather, available literature was qualitatively synthesized and presented. For FALD prognosis, all studies that evaluated association between any FALD parameters and clinical outcomes were selected. Clinical outcomes included all-cause mortality, cardiovascular mortality, heart or liver transplantation, ventricular assist device implantation, cardiovascular hospitalization, thromboembolic event, arrhythmias, protein-losing enteropathy, plastic bronchitis, and HCC. For FALD management, any study that reported any pharmacological or surgical strategies with associated outcomes was selected.</p></sec><sec id="sec1.3"><title>Data analysis</title><p id="p0045">Event rates were extracted for dichotomous outcomes and mean and SD for continuous outcomes. Where median and IQR or minimum-maximum range was reported, a validated method was used to convert to mean and SD.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> A random-effects model using a random-intercept logistic regression with maximum likelihood estimator was employed to account for differences in patient characteristics and procedural factors between studies.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Subgroup analyses by diagnostic method and patient selection method and post hoc univariable meta-regression were performed to explore variables that might have contributed toward the heterogeneity in the summary effect sizes. Sensitivity analyses using the leave-one-out method were undertaken to assess the robustness of the outcomes.</p><p id="p0050">Publication bias was assessed visually by funnel plots and statistically by Begg test. All statistical analyses were carried out using R Statistical Software (v4.3.1, R Core Team 2021).</p></sec></sec><sec id="sec2"><title>Results</title><p id="p0055">The search results are shown in <xref rid="mmc1" ref-type="supplementary-material">Supplemental Figure&#x000a0;1</xref> in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart. Thirty-seven studies were included for statistical synthesis, comprising 5,701 patients, followed up for a median of 17&#x000a0;years (IQR: 14-20&#x000a0;years) post-Fontan completion. Study characteristics are summarized in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Study and Patient Baseline Variables</p></caption><table frame="hsides" rules="groups"><thead><tr><th>First Author, Year</th><th>Selection</th><th>N</th><th>Diagnostic Method</th><th>Age at Fontan Completion, y</th><th>Fontan Type (%)</th><th>&#x02265; Mod Ventricular Dysfunction (%)</th><th>&#x02265; Mod AVVR (%)</th></tr></thead><tbody><tr><td>Zentner et&#x000a0;al, 2023<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></td><td align="center">Unselected</td><td align="center">70</td><td align="center">Imaging</td><td align="center">5.3</td><td align="center">AP 43, ECC 42, LT 15</td><td align="center">12</td><td/></tr><tr><td>Zafar et&#x000a0;al, 2022<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></td><td align="center">Unselected</td><td align="center">123</td><td align="center">Imaging</td><td align="center">6.5</td><td align="center">AP 15, ECC 44, LT 41</td><td align="center">13</td><td align="center">18</td></tr><tr><td>Inuzuka et&#x000a0;al, 2022<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></td><td align="center">Unselected</td><td align="center">1,117</td><td align="center">Mixed</td><td align="center">4</td><td/><td/><td align="center">15</td></tr><tr><td>Gunsaulus et&#x000a0;al, 2022<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></td><td align="center">Unclear</td><td align="center">44</td><td align="center">Imaging</td><td align="center">3.03</td><td/><td align="center">8</td><td align="center">6</td></tr><tr><td>Thrane et&#x000a0;al, 2021<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref></td><td align="center">Unselected</td><td align="center">46</td><td align="center">Biopsy<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">2.6</td><td/><td/><td/></tr><tr><td>Shin et&#x000a0;al, 2021<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></td><td align="center">Unclear</td><td align="center">45</td><td align="center">Biopsy</td><td align="center">5.3</td><td align="center">AP 27, ECC 24, LT 49</td><td/><td align="center">11</td></tr><tr><td>Sakamori et&#x000a0;al, 2021<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref></td><td align="center">Unselected</td><td align="center">103</td><td align="center">Mixed<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">3</td><td align="center">AP 11, ECC 66, LT 23</td><td/><td/></tr><tr><td>Ohuchi et&#x000a0;al, 2021<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></td><td align="center">Unselected</td><td align="center">339</td><td align="center">Biopsy<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">2.3</td><td/><td/><td/></tr><tr><td>Navallas et&#x000a0;al, 2021<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref></td><td align="center">Unselected</td><td align="center">37</td><td align="center">Imaging</td><td align="center">3.33</td><td align="center">AP 0, ECC 97, LT 3</td><td/><td/></tr><tr><td>Martinez-Quintana and Rodriguez-Gonzalez, 2021<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref></td><td align="center">Unselected</td><td align="center">14</td><td align="center">Imaging</td><td align="center">9.4</td><td/><td/><td/></tr><tr><td>Langguth et&#x000a0;al, 2021<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></td><td align="center">Unselected</td><td align="center">28</td><td align="center">Imaging</td><td align="center">2.9</td><td align="center">AP 0, ECC 7, LT 93</td><td/><td/></tr><tr><td>Hansen et&#x000a0;al, 2021<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></td><td align="center">Unselected</td><td align="center">240</td><td align="center">Imaging</td><td align="center">2.7</td><td align="center">AP 1, ECC 11, LT 88</td><td/><td align="center">20</td></tr><tr><td>Emamaullee et&#x000a0;al, 2021<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></td><td align="center">Unselected</td><td align="center">106</td><td align="center">Biopsy</td><td align="center">3.5</td><td align="center">AP 0, ECC 93, LT 7</td><td align="center">7</td><td align="center">29</td></tr><tr><td>De Bruyne et&#x000a0;al, 2021<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref></td><td align="center">Unselected</td><td align="center">35</td><td align="center">Imaging</td><td align="center">3.34</td><td align="center">AP 0, ECC 69, LT 31</td><td/><td align="center">6</td></tr><tr><td>Chemello et&#x000a0;al, 2021<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref></td><td align="center">Unselected</td><td align="center">43</td><td align="center">Imaging</td><td align="center">3.5</td><td align="center">AP 1, ECC 47, LT 44</td><td/><td/></tr><tr><td>Anigwe et&#x000a0;al, 2021<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref></td><td align="center">Unclear</td><td align="center">160</td><td align="center">Imaging</td><td align="center">7.07</td><td align="center">AP 0, ECC 73, LT 27</td><td/><td align="center">28</td></tr><tr><td>Yoon et&#x000a0;al, 2020<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></td><td align="center">Unselected</td><td align="center">313</td><td align="center">Imaging</td><td align="center">2.9</td><td align="center">AP 17, ECC 43, LT 40</td><td/><td/></tr><tr><td>Wan et&#x000a0;al, 2020<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref></td><td align="center">Unselected</td><td align="center">93</td><td align="center">Imaging</td><td align="center">7.9</td><td align="center">AP 30, ECC 32, LT 38</td><td/><td align="center">18</td></tr><tr><td>Tellez et&#x000a0;al, 2020<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></td><td align="center">Unselected</td><td align="center">152</td><td align="center">Biopsy<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">9</td><td align="center">AP 27, ECC 64, LT 9</td><td/><td/></tr><tr><td>Sethasathien et&#x000a0;al, 2020<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></td><td align="center">Unclear</td><td align="center">80</td><td align="center">Imaging</td><td align="center">7.75</td><td align="center">AP 3, ECC 98, LT 0</td><td/><td align="center">19</td></tr><tr><td>Abbasi et&#x000a0;al, 2020<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref></td><td align="center">Unclear</td><td align="center">30</td><td align="center">Imaging</td><td align="center">11.9</td><td align="center">AP 37, ECC 43, LT 20</td><td/><td align="center">3</td></tr><tr><td>SmasSuska et&#x000a0;al, 2019<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></td><td align="center">Unselected</td><td align="center">59</td><td align="center">Imaging</td><td align="center">7</td><td align="center">AP 7, ECC 93, LT 0</td><td/><td align="center">19</td></tr><tr><td>Silva-Sepulveda et&#x000a0;al, 2019<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref></td><td align="center">Unselected</td><td align="center">28</td><td align="center">Imaging</td><td/><td align="center">AP 3, ECC 38, LT 59</td><td align="center">2</td><td align="center">4</td></tr><tr><td>Munsterman et&#x000a0;al, 2019<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref></td><td align="center">Unselected</td><td align="center">38</td><td align="center">Mixed</td><td align="center">4.77</td><td align="center">AP 39, ECC 42, LT 19</td><td align="center">2</td><td/></tr><tr><td>Wilson et&#x000a0;al, 2018<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref></td><td align="center">Unselected</td><td align="center">1,552</td><td align="center">Biopsy<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td/><td/><td/><td/></tr><tr><td>Song et&#x000a0;al, 2018<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref></td><td align="center">Unselected</td><td align="center">26</td><td align="center">Imaging</td><td align="center">9.3</td><td align="center">AP 0, ECC 96, LT 4</td><td align="center">0</td><td align="center">6</td></tr><tr><td>Schachter et&#x000a0;al, 2018<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref></td><td align="center">Unselected</td><td align="center">14</td><td align="center">Biopsy</td><td/><td/><td/><td/></tr><tr><td>Nandwana et&#x000a0;al, 2018<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref></td><td align="center">Unclear</td><td align="center">145</td><td align="center">Imaging</td><td align="center">4.25</td><td/><td/><td/></tr><tr><td>Kim et&#x000a0;al, 2018<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref></td><td align="center">Unclear</td><td align="center">64</td><td align="center">Imaging</td><td align="center">5.4</td><td align="center">AP 2, ECC 84, LT 14</td><td/><td/></tr><tr><td>Egbe et&#x000a0;al, 2018<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref></td><td align="center">Unclear</td><td align="center">164</td><td align="center">Mixed</td><td align="center">8</td><td/><td/><td/></tr><tr><td>Buendia et&#x000a0;al, 2018<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref></td><td align="center">Unselected</td><td align="center">37</td><td align="center">Imaging</td><td align="center">6.3</td><td align="center">AP 16, ECC 65, LT 19</td><td align="center">7</td><td align="center">6</td></tr><tr><td>Surrey et&#x000a0;al, 2016<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref></td><td align="center">Unselected</td><td align="center">74</td><td align="center">Biopsy</td><td align="center">4.15</td><td align="center">AP 5, ECC 34, LT 61</td><td/><td/></tr><tr><td>Agnoletti et&#x000a0;al, 2016<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></td><td align="center">Unselected</td><td align="center">64</td><td align="center">Mixed</td><td align="center">8.83</td><td/><td/><td align="center">11</td></tr><tr><td>Poterucha et&#x000a0;al, 2015<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref></td><td align="center">Unclear</td><td align="center">50</td><td align="center">Biopsy<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">4</td><td align="center">AP 40, ECC 26, LT 34</td><td/><td align="center">16</td></tr><tr><td>Lindsay et&#x000a0;al, 2015<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></td><td align="center">Unclear</td><td align="center">53</td><td align="center">Imaging</td><td align="center">6.65</td><td/><td/><td/></tr><tr><td>Wallihan et&#x000a0;al, 2013<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref></td><td align="center">Unclear</td><td align="center">42</td><td align="center">Imaging</td><td align="center">9.53</td><td align="center">AP 29, ECC 29, LT 43</td><td/><td/></tr><tr><td>Elder et&#x000a0;al, 2013<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref></td><td align="center">Unclear</td><td align="center">73</td><td align="center">Imaging</td><td/><td align="center">AP 36, ECC 12, LT 52</td><td align="center">12</td><td align="center">Unclear</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th>CVP (mm&#x000a0;Hg)</th><th>PCWP (mm&#x000a0;Hg)</th><th>PVR (WU)</th><th>MELD-XI</th><th>Follow-Up Post-Fontan (y)</th><th>Ref #</th></tr></thead><tbody><tr><td/><td/><td/><td align="center">29</td><td align="center">24</td><td align="center"><xref rid="bib11" ref-type="bibr">11</xref></td></tr><tr><td>13</td><td/><td align="center">1.43</td><td/><td/><td align="center"><xref rid="bib33" ref-type="bibr">33</xref></td></tr><tr><td>12.8</td><td align="center">7</td><td align="center">2</td><td/><td align="center">15</td><td align="center"><xref rid="bib8" ref-type="bibr">8</xref></td></tr><tr><td>13</td><td/><td align="center">1.43</td><td/><td align="center">16.2</td><td align="center"><xref rid="bib34" ref-type="bibr">34</xref></td></tr><tr><td/><td/><td/><td/><td align="center">14.1</td><td align="center"><xref rid="bib35" ref-type="bibr">35</xref></td></tr><tr><td>14</td><td/><td/><td/><td align="center">20.8</td><td align="center"><xref rid="bib36" ref-type="bibr">36</xref></td></tr><tr><td/><td/><td/><td/><td align="center">19.6</td><td align="center"><xref rid="bib63" ref-type="bibr">63</xref></td></tr><tr><td>10</td><td/><td/><td/><td align="center">25.6</td><td align="center"><xref rid="bib28" ref-type="bibr">28</xref></td></tr><tr><td/><td/><td/><td/><td/><td align="center"><xref rid="bib38" ref-type="bibr">38</xref></td></tr><tr><td/><td/><td/><td align="center">24.3</td><td align="center">16.5</td><td align="center"><xref rid="bib39" ref-type="bibr">39</xref></td></tr><tr><td/><td/><td/><td/><td align="center">14.63</td><td align="center"><xref rid="bib40" ref-type="bibr">40</xref></td></tr><tr><td>11</td><td/><td/><td/><td/><td align="center"><xref rid="bib41" ref-type="bibr">41</xref></td></tr><tr><td>12.9</td><td/><td align="center">1.7</td><td align="center">14.4</td><td align="center">10.8</td><td align="center"><xref rid="bib42" ref-type="bibr">42</xref></td></tr><tr><td/><td/><td/><td/><td align="center">7.31</td><td align="center"><xref rid="bib43" ref-type="bibr">43</xref></td></tr><tr><td/><td/><td/><td/><td/><td align="center"><xref rid="bib44" ref-type="bibr">44</xref></td></tr><tr><td>13.6</td><td align="center">10.3</td><td align="center">0.96</td><td/><td align="center">15.9</td><td align="center"><xref rid="bib45" ref-type="bibr">45</xref></td></tr><tr><td>13</td><td/><td/><td align="center">20</td><td align="center">20</td><td align="center"><xref rid="bib15" ref-type="bibr">15</xref></td></tr><tr><td/><td/><td/><td/><td/><td align="center"><xref rid="bib46" ref-type="bibr">46</xref></td></tr><tr><td>14.9</td><td/><td/><td align="center">10.8</td><td align="center">18.3</td><td align="center"><xref rid="bib47" ref-type="bibr">47</xref></td></tr><tr><td>15.3</td><td/><td align="center">3.3</td><td/><td align="center">8.43</td><td align="center"><xref rid="bib48" ref-type="bibr">48</xref></td></tr><tr><td>17.25</td><td/><td/><td/><td align="center">18.85</td><td align="center"><xref rid="bib49" ref-type="bibr">49</xref></td></tr><tr><td/><td/><td/><td align="center">29</td><td align="center">19.67</td><td align="center"><xref rid="bib50" ref-type="bibr">50</xref></td></tr><tr><td>13</td><td align="center">7.8</td><td align="center">1.6</td><td/><td align="center">16.73</td><td align="center"><xref rid="bib51" ref-type="bibr">51</xref></td></tr><tr><td/><td/><td/><td align="center">27.6</td><td align="center">21.4</td><td align="center"><xref rid="bib52" ref-type="bibr">52</xref></td></tr><tr><td/><td/><td/><td/><td align="center">12.7</td><td align="center"><xref rid="bib64" ref-type="bibr">64</xref></td></tr><tr><td>12.8</td><td/><td align="center">1.5</td><td/><td align="center">10.5</td><td align="center"><xref rid="bib5" ref-type="bibr">5</xref></td></tr><tr><td/><td/><td/><td/><td align="center">24.7</td><td align="center"><xref rid="bib54" ref-type="bibr">54</xref></td></tr><tr><td/><td/><td/><td/><td align="center">23.92</td><td align="center"><xref rid="bib55" ref-type="bibr">55</xref></td></tr><tr><td>14.1</td><td/><td align="center">1.35</td><td/><td align="center">12.1</td><td align="center"><xref rid="bib56" ref-type="bibr">56</xref></td></tr><tr><td/><td/><td/><td/><td align="center">26.67</td><td align="center"><xref rid="bib57" ref-type="bibr">57</xref></td></tr><tr><td/><td/><td/><td align="center">22.9</td><td align="center">15.8</td><td align="center"><xref rid="bib58" ref-type="bibr">58</xref></td></tr><tr><td>14</td><td/><td/><td/><td align="center">14.55</td><td align="center"><xref rid="bib59" ref-type="bibr">59</xref></td></tr><tr><td>12</td><td align="center">15.3</td><td align="center">3</td><td align="center">13.83</td><td align="center">12.75</td><td align="center"><xref rid="bib60" ref-type="bibr">60</xref></td></tr><tr><td>16</td><td align="center">10</td><td align="center">3</td><td align="center">9</td><td align="center">22</td><td align="center"><xref rid="bib23" ref-type="bibr">23</xref></td></tr><tr><td/><td/><td/><td/><td align="center">18</td><td align="center"><xref rid="bib16" ref-type="bibr">16</xref></td></tr><tr><td/><td/><td/><td/><td align="center">14.6</td><td align="center"><xref rid="bib65" ref-type="bibr">65</xref></td></tr><tr><td/><td/><td/><td/><td/><td align="center"><xref rid="bib62" ref-type="bibr">62</xref></td></tr></tbody></table><table-wrap-foot><fn><p>AP&#x000a0;=&#x000a0;atriopulmonary; AVVR&#x000a0;=&#x000a0;atrioventricular valvular regurgitation; CVP&#x000a0;=&#x000a0;central venous pressure; ECC&#x000a0;=&#x000a0;extracardiac conduit; LT&#x000a0;=&#x000a0;lateral tunnel; MELD-XI&#x000a0;=&#x000a0;Model for End-stage Liver Disease excluding INR; PVR&#x000a0;=&#x000a0;pulmonary vascular resistance.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Studies that reported hepatocellular carcinoma as the only liver-related outcome, so the diagnostic method refers to the diagnosis of the malignancy only.</p></fn></table-wrap-foot></table-wrap></p><p id="p0060">Nineteen studies reported the primary pathology, comprising 1,715 patients. Tricuspid atresia was the most common in 571 (33%) patients, followed by hypoplastic left heart syndrome in 432 (25%), double inlet left ventricle in 203 (12%), pulmonary atresia in 135 (8%), and double outlet right ventricle in 108 (6%) patients. The median age at Fontan completion was 5.3&#x000a0;years (IQR: 3.3-7.8&#x000a0;years). Twenty-three studies reported on Fontan connection type, comprising 1,844 patients. This included extracardiac conduit in 981 (53%) patients, lateral tunnel in 661 (36%) patients, and atriopulmonary (AP) in 267 (15%) patients. Other baseline patient characteristics and presurgical and surgical variables are summarized in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>.</p><sec id="sec2.1"><title>Liver outcomes</title><p id="p0065">Cirrhosis, advanced fibrosis, and&#x000a0;portal hypertension were defined in various methods between studies (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Table&#x000a0;1</xref>). HCC diagnosis was either undefined or by a combination of imaging or biopsy. Of the 26 studies reporting cirrhosis prevalence, there were 8 different, albeit overlapping, definitions of cirrhosis, and this was likewise observed for advanced fibrosis and portal hypertension. Overlapping imaging features included liver surface nodularity, heterogeneous echogenicity, and caudate lobe hypertrophy. Biopsies were scored using various systems that focused either on portal or centrilobular fibrosis. Cirrhosis was reported in 21% (95%&#x000a0;CI: 13%-30%) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>) of the cohort at a median of 16&#x000a0;years follow-up post-Fontan completion, or approximately 47,000 patient-years. Advanced fibrosis without cirrhosis was reported in 30% (95%&#x000a0;CI: 23%-39%; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2A</xref>) of patients, portal hypertension in 17% (95%&#x000a0;CI: 8%-31%; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2B</xref>) and HCC in 2% (95%&#x000a0;CI: 1%-3%; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2C</xref>). The median follow-up post-Fontan completion for only studies reporting HCC was 18&#x000a0;years (IQR: 15-21&#x000a0;years).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Prevalence of Cirrhosis Using Random-Effects Model</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Prevalence of Advanced Fibrosis, Portal Hypertension and Hepatocellular Carcinoma</p><p>(A) Prevalence of advanced fibrosis without cirrhosis, (B) portal hypertension and (C) hepatocellular carcinoma.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0070">Significant heterogeneity was noted in all 3 outcomes (<italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;79%-96%, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). The rate of cirrhosis ranged between 0% in Song et&#x000a0;al<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> with 10&#x000a0;years of follow-up to 76% in Zentner et&#x000a0;al<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> with 24&#x000a0;years of follow-up. Subgroup analysis by categorizing studies into those that have specified nonselective liver screening vs those without clear selection criteria noted a significantly lower rate of cirrhosis in the former group (14% vs 31%, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Figure&#x000a0;2</xref>). This implied that certain studies that have not specified selection criteria might have included a higher risk population for liver disease. Subgroup analysis by diagnostic method revealed that those studies with only biopsy-proven cirrhosis found a trend toward lower rate of cirrhosis than those with only imaging-proven cirrhosis (10% vs 26%, <italic>P</italic>&#x000a0;=&#x000a0;0.09) (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Figure&#x000a0;3</xref>).</p><p id="p0075">Exploratory meta-regression evaluated potential predictors of cirrhosis. A linear relationship was found between years post-Fontan completion and odds of cirrhosis, although notably the shortest follow-up was 7.3&#x000a0;years, so whether a linear relationship exists before this is unclear. Every year post-Fontan completion conferred 11% increased odds of developing cirrhosis (95%&#x000a0;CI:&#x000a0;1.02-1.22; <italic>P</italic>&#x000a0;=&#x000a0;0.02; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>) with the predicted prevalence of cirrhosis at 10, 15, and 20&#x000a0;years being 13%, 23%, and 33%, respectively. This relationship remained significant when including only studies specifying unselected liver screening in patients (OR:&#x000a0;1.02/year; 95% CI: 1.00-1.04; <italic>P</italic>&#x000a0;=&#x000a0;0.04). Likewise, pulmonary capillary wedge pressure (PCWP), the proportion of AP Fontan, and of patients with at least moderate ventricular dysfunction were found to be predictors of cirrhosis (PCWP: OR&#x000a0;=&#x000a0;1.27/mm&#x000a0;Hg increase, 95%&#x000a0;CI: 1.18-1.37; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001; AP Fontan: OR:&#x000a0;1.69/10% increase; 95%&#x000a0;CI: 1.23-2.27, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001; ventricular dysfunction: OR: 5.9/10% increase; 95%&#x000a0;CI: 1.2-29.6, <italic>P</italic>&#x000a0;=&#x000a0;0.03) (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Figures&#x000a0;4 to 6</xref>). A trend toward a positive relationship was found between central venous pressure (CVP) and risk of cirrhosis (OR:&#x000a0;1.57/mm&#x000a0;Hg increase; 95%&#x000a0;CI:&#x000a0;0.95-2.61; <italic>P</italic>&#x000a0;=&#x000a0;0.08) (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Figure&#x000a0;7</xref>). The Model for&#x000a0;End-stage Liver Disease excluding INR score (MELD-XI) was not associated with the risk of cirrhosis in the current analysis (OR:&#x000a0;0.73; 95%&#x000a0;CI: 0.41-1.27; <italic>P</italic>&#x000a0;=&#x000a0;0.26). Results of univariable meta-regressions are summarized in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Positive Correlation Between Years Post-Fontan Completion and Cirrhosis Prevalence</p></caption><graphic xlink:href="gr3"/></fig><table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Univariable Meta-Regression Between Baseline Presurgical and Surgical Variables and Risk of Cirrhosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>N</th><th>OR (95%&#x000a0;CI)</th><th><italic>P</italic> Value</th></tr></thead><tbody><tr><td>Years post-Fontan completion (per year)</td><td align="center">26</td><td align="center">1.11 (1.02-1.22)</td><td align="center"><bold>0.02</bold></td></tr><tr><td>Gender (per 10% increase in male)</td><td align="center">25</td><td align="center">0.84 (0.58-1.23)</td><td align="center">0.37</td></tr><tr><td>Age at Fontan completion (per&#x000a0;year)</td><td align="center">24</td><td align="center">1.01 (0.81-1.22)</td><td align="center">0.94</td></tr><tr><td>CVP (per mm&#x000a0;Hg)</td><td align="center">13</td><td align="center">1.57 (0.95-2.61)</td><td align="center">0.08</td></tr><tr><td>PVR (per Woods unit)</td><td align="center">9</td><td align="center">1.19 (0.45-3.12)</td><td align="center">0.73</td></tr><tr><td>PCWP (per mm&#x000a0;Hg)</td><td align="center">4</td><td align="center">1.27 (1.18-1.37)</td><td align="center"><bold>&#x0003c;0.001</bold></td></tr><tr><td>Fontan type (per 10% increase in AP proportion)</td><td align="center">18</td><td align="center">1.69 (1.23-2.27)</td><td align="center"><bold>&#x0003c;0.001</bold></td></tr><tr><td>Fenestration (per 10% increase)</td><td align="center">13</td><td align="center">1.04 (0.69-1.58)</td><td align="center">0.85</td></tr><tr><td>MELD XI (per score)</td><td align="center">8</td><td align="center">0.73 (0.41-1.27)</td><td align="center">0.26</td></tr><tr><td>&#x02265;Moderate ventricular dysfunction (per 10% increase in proportion)</td><td align="center">7</td><td align="center">5.91 (1.18-29.61)</td><td align="center"><bold>0.03</bold></td></tr><tr><td>&#x02265;Moderate AVVR (per 10% increase in proportion)</td><td align="center">14</td><td align="center">0.90 (0.42-1.93)</td><td align="center">0.79</td></tr></tbody></table><table-wrap-foot><fn id="tspara0040"><p>Bold values denote <italic>P</italic> &#x0003c; 0.05.</p></fn><fn id="tspara0025"><p>N&#x000a0;=&#x000a0;number of studies; PCWP&#x000a0;=&#x000a0;pulmonary capillary wedge pressure; other abbreviations as in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.2"><title>Prognosis and management strategies</title><p id="p0080">Various studies have evaluated the prognostic value of liver injury on cardiovascular and hepatic outcomes, as well as overall mortality. However, due to the significant hetereogeneity in the prognostic markers and outcomes evaluated, statistical synthesis was not possible. As such, <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref> systematically summarizes the existing data, with most studies suggesting that liver injury portends unfavorable long-term clinical outcomes including all-cause mortality, need for heart transplantation or ventricular assist device, and decompensated heart failure. In contrast, only 3 studies on management strategies of FALD were identified. Glenn et&#x000a0;al<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> examined the effect of phosphodiesterase type 5 inhibitors on histological progression of FALD and found no consistent effect, although this was severely limited by low number of patients with pre- and post-therapy biopsies. Two further case series of isolated heart transplant recipients found overall improvement in fibrosis features on imaging post-transplant.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Summary of Studies Evaluating Prognostic Role of Liver Disease in Fontan Patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Diagnostic Method<hr/></th><th>Endpoint<hr/></th><th>Association, Effect Estimator/Size, <italic>P</italic> Value<hr/></th><th rowspan="2">Ref #</th></tr><tr><th colspan="3">Imaging</th></tr></thead><tbody><tr><td>Ultrasound</td><td/><td/><td/></tr><tr><td>&#x000a0;Liver volume/BSA</td><td><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0170">Death, heart/liver transplantation</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher volume/BSA, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.037</td><td align="center"><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref></td></tr><tr><td>&#x000a0;Composite score<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td><list list-type="simple" id="ulist0015"><list-item id="u0015"><label>&#x02022;</label><p id="p0175">HCC</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher score, HR: 5.99, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</td><td align="center"><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></td></tr><tr><td>&#x000a0;Stiffness (ARFI)</td><td><list list-type="simple" id="ulist0020"><list-item id="u0020"><label>&#x02022;</label><p id="p0180">Death, heart transplantation, ventricular assist device implantation, decompensated heart failure</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher stiffness, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.04</td><td align="center"><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref></td></tr><tr><td/><td><list list-type="simple" id="ulist0025"><list-item id="u0025"><label>&#x02022;</label><p id="p0185">Thromboembolic events</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher stiffness, OR: 2.12, <italic>P</italic>&#x000a0;=&#x000a0;0.03</td><td align="center"><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref></td></tr><tr><td/><td><list list-type="simple" id="ulist0030"><list-item id="u0030"><label>&#x02022;</label><p id="p0190">Death, heart transplantation, HCC, varices</p></list-item></list></td><td align="left">Not a predictor, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.127</td><td align="center"><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></td></tr><tr><td>MRI</td><td/><td/><td/></tr><tr><td>&#x000a0;Liver volume</td><td><list list-type="simple" id="ulist0035"><list-item id="u0035"><label>&#x02022;</label><p id="p0195">Death, heart transplantation, ventricular assist device implantation, nonelective cardiovascular hospitalization</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p0200">Death, heart transplantation, decompensated heart failure</p></list-item></list></td><td>Higher risk&#x000a0;&#x0221d;&#x000a0;higher volume, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.01<break/>Not a predictor, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.28</td><td align="center"><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><break/><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></td></tr><tr><td>&#x000a0;Stiffness</td><td><list list-type="simple" id="ulist0040"><list-item id="u0045"><label>&#x02022;</label><p id="p0205">Death, heart transplantation, decompensated heart failure</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher stiffness, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.03</td><td align="center"><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></td></tr><tr><td>&#x000a0;Cirrhosis<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td><list list-type="simple" id="ulist0045"><list-item id="u0050"><label>&#x02022;</label><p id="p0210">Death, listing for heart transplantation, arrhythmias, protein-losing enteropathy, decompensated heart failure</p></list-item></list></td><td align="left">Not a predictor, chi-square, <italic>P</italic>&#x000a0;=&#x000a0;0.77</td><td align="center"><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref></td></tr><tr><td>Biopsy</td><td/><td/><td/></tr><tr><td>&#x000a0;CHFS grade 3-4</td><td><list list-type="simple" id="ulist0050"><list-item id="u0055"><label>&#x02022;</label><p id="p0215">Death</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher biopsy grade, MD, <italic>P</italic>&#x000a0;=&#x000a0;0.027</td><td align="center"><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></td></tr><tr><td>&#x000a0;Combined portal sinusoidal fibrosis</td><td><list list-type="simple" id="ulist0055"><list-item id="u0060"><label>&#x02022;</label><p id="p0220">Protein-losing enteropathy</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;more fibrosis, chi-square, <italic>P</italic>&#x000a0;=&#x000a0;0.003</td><td align="center"><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></td></tr><tr><td>&#x000a0;Centrilobular fibrosis<break/>Portal fibrosis</td><td><list list-type="simple" id="ulist0060"><list-item id="u0065"><label>&#x02022;</label><p id="p0225">Death, heart transplantation</p></list-item><list-item id="u0070"><label>&#x02022;</label><p id="p0230">Death, heart transplantation</p></list-item></list></td><td>Not a predictor, OR:&#x000a0;1.3, <italic>P</italic>&#x000a0;=&#x000a0;0.69<break/>Not a predictor, OR:&#x000a0;0.6, <italic>P</italic>&#x000a0;=&#x000a0;0.38</td><td align="center"><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><break/><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></td></tr><tr><td>Mixed</td><td/><td/><td/></tr><tr><td>&#x000a0;Cirrhosis<xref rid="tbl3fnc" ref-type="table-fn">c</xref></td><td><list list-type="simple" id="ulist0065"><list-item id="u0075"><label>&#x02022;</label><p id="p0235">Death</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;cirrhosis, HR: 2.7, <italic>P</italic>&#x000a0;=&#x000a0;0.08</td><td align="center"><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></td></tr><tr><td>&#x000a0;Cirrhosis<xref rid="tbl3fnd" ref-type="table-fn">d</xref></td><td><list list-type="simple" id="ulist0070"><list-item id="u0080"><label>&#x02022;</label><p id="p0240">HCC</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;cirrhosis, chi-square, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</td><td align="center"><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref></td></tr><tr><td>&#x000a0;Cirrhosis<xref rid="tbl3fne" ref-type="table-fn">e</xref></td><td><list list-type="simple" id="ulist0075"><list-item id="u0085"><label>&#x02022;</label><p id="p0245">Arrhythmias</p></list-item><list-item id="u0090"><label>&#x02022;</label><p id="p0250">Thromboembolic events</p></list-item></list></td><td>Higher risk&#x000a0;&#x0221d;&#x000a0;cirrhosis, OR: 6.9, <italic>P</italic>&#x000a0;=&#x000a0;0.06<break/>Higher risk&#x000a0;&#x0221d;&#x000a0;cirrhosis, OR: 5.4, <italic>P</italic>&#x000a0;=&#x000a0;0.04</td><td align="center"><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><break/><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref></td></tr><tr><td>&#x000a0;Cirrhosis<xref rid="tbl3fnf" ref-type="table-fn">f</xref></td><td><list list-type="simple" id="ulist0080"><list-item id="u0095"><label>&#x02022;</label><p id="p0255">Protein-losing enteropathy</p></list-item></list></td><td align="left">Not a predictor, chi-square, <italic>P</italic>&#x000a0;=&#x000a0;0.12</td><td align="center"><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></td></tr><tr><td>&#x000a0;Composite score<xref rid="tbl3fng" ref-type="table-fn">g</xref></td><td><list list-type="simple" id="ulist0085"><list-item id="u0100"><label>&#x02022;</label><p id="p0260">Death</p></list-item></list></td><td align="left">Higher risk&#x000a0;&#x0221d;&#x000a0;higher score, chi-square, <italic>P</italic>&#x000a0;=&#x000a0;0.018</td><td align="center"><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></td></tr><tr><td>&#x000a0;VAST&#x000a0;&#x02265;2<xref rid="tbl3fnh" ref-type="table-fn">h</xref></td><td><list list-type="simple" id="ulist0090"><list-item id="u0105"><label>&#x02022;</label><p id="p0265">Death, heart transplantation, HCC</p></list-item><list-item id="u0110"><label>&#x02022;</label><p id="p0270">Death, heart transplantation, ventricular assist device implantation, decompensated heart failure</p></list-item></list></td><td>Higher risk&#x000a0;&#x0221d;&#x000a0;VAST&#x000a0;&#x02265;2, OR: 9.8, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05<break/>Higher risk&#x000a0;&#x0221d;&#x000a0;VAST&#x000a0;&#x02265;2, OR: 10.2, <italic>P</italic>&#x000a0;=&#x000a0;0.003</td><td align="center"><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><break/><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>ARFI&#x000a0;=&#x000a0;acoustic radiation force impulse; BSA&#x000a0;=&#x000a0;body surface area; AST = aspartate aminotransferase; CHFS&#x000a0;=&#x000a0;congestive hepatic fibrosis score; GGT = gamma glutamyl transferase; HCC&#x000a0;=&#x000a0;hepatocellular carcinoma; MD&#x000a0;=&#x000a0;mean difference in liver imaging marker between those who reached the endpoint or not; MRI&#x000a0;=&#x000a0;magnetic resonance imaging; VAST = Varices, Ascites, Splenomegaly or Thrombocytopenia.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0015">Parenchymal echotexture (normal&#x000a0;=&#x000a0;0, coarse&#x000a0;=&#x000a0;1), surface irregularity (smooth&#x000a0;=&#x000a0;0, irregular&#x000a0;=&#x000a0;1), ascites (nonsmall&#x000a0;=&#x000a0;0,&#x000a0;&#x02265; moderate&#x000a0;=&#x000a0;1), number of hyperechoic spots (&#x02265;3&#x000a0;mm in diameter; none to a few&#x000a0;=&#x000a0;0, larger number&#x000a0;=&#x000a0;1), and space-occupying lesions (no&#x000a0;=&#x000a0;0, yes&#x000a0;=&#x000a0;1).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0020">Both lobulation and nodularity.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnc"><label>c</label><p id="ntpara0025">Liver stiffness &#x0003e;5 kPA on magnetic resonance elastography or stage 4 fibrosis on biopsy.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnd"><label>d</label><p id="ntpara0030">Biopsy or imaging features plus varices and splenomegaly.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fne"><label>e</label><p id="ntpara0035">Undefined.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnf"><label>f</label><p id="ntpara0040">Biopsy or imaging features (parenchymal heterogeneity with irregular undulating liver margins and caudate hypertrophy with or without enhancing nodules).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fng"><label>g</label><p id="ntpara0045">Ultrasound (surface nodularity/blunted liver edge, heterogenous parenchyma/echo bright lesions, ascites, splenomegaly, abnormal portal vein flow) and laboratory abnormalities (thrombocytopenia, elevated GGT, elevated AST, prothrombin activity&#x000a0;&#x0003c;70%, and hypoalbuminaemia).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnh"><label>h</label><p id="ntpara0050">Varices, ascites, splenomegaly, and platelet&#x000a0;&#x02264;150.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.3"><title>Sensitivity analysis and publication bias</title><p id="p0085">Sensitivity analysis using the &#x0201c;leave-one-out&#x0201d; method revealed that no study had a disproportionate impact on the primary outcome (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Figure&#x000a0;8</xref>). There were no publication biases as visually assessed by the funnel plots and confirmed statistically by Begg test (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Figure&#x000a0;9</xref>).</p></sec></sec><sec id="sec3"><title>Conclusions</title><p id="p0090">FALD encompasses a spectrum of liver disease that is commonly seen in patients living with Fontan circulation. Despite increasing recognition, there remain significant practice differences in screening for FALD, likely stemming from inconsistent data on its risk factors, diagnostic method, and prognostic significance. The current study is the first systematic attempt to provide an unbiased summary of prevalence, diagnosis, risk factors, and prognosis of FALD in those routinely screened. Despite this, the key findings of our review reflect the significant heterogeneity in outcomes as a result of variable institutional practices and patient factors (<xref rid="fig4" ref-type="fig">Central Illustration</xref>). Importantly, we have noted various factors contributing toward such heterogeneity including diagnostic method, time after Fontan completion, type of Fontan circulation, ventricular dysfunction, and PCWP. These factors should be considered in clinical practice in evaluating the pretest probability of FALD in individual patients, as well as in designing structured screening programs.<fig id="fig4"><label>Central Illustration</label><caption><p>Call to Action for a Uniform and Prognostically Meaningful Definition of Fontan-Associated Liver Disease, Given Existing Heterogeneity in the Current Literature</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0095">Prevalence of FALD differed markedly between studies. Indeed, between the 26 studies reporting cirrhosis, we noted 8 different definitions of cirrhosis, which should serve as impetus for more unifying definitions of FALD in future studies. Despite attempting to minimize the confounding effect of patient selection on risk of liver disease by excluding studies with selective liver screening, the reported cirrhosis rate still varied from 0 to 76%, and likewise for advanced fibrosis, portal hypertension, and HCC. Large cohort studies were not immune to such variations, suggesting that the difference is likely underpinned by diagnostic method and criteria rather than random variations. The largest cohort consisted of 1,117 Japanese Fontan patients, and estimated incidence of biopsy or imaging-proven cirrhosis was 4% at 15&#x000a0;years post-Fontan completion.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> In contrast, a multicenter Korean study of 313 patients who were routinely screened for liver disease via ultrasound or computed tomography noted just over half of all patients having cirrhosis at 20&#x000a0;years follow-up post-Fontan completion.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p><p id="p0100">Given the lack of consensus on the most practical and prognostically meaningful definition of FALD, a spectrum of invasive and noninvasive tools has been evaluated. Serological tests are often of questionable prognostic significance in FALD and thus excluded from our analyses. Liver function tests are commonly performed but do not correlate well with the severity of liver injury.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> More nuanced serological panels that predict cirrhosis in viral hepatitis have not proven to be useful for FALD. The aspartate aminotransferase-to-platelet ratio score and the Fibrosis-4 score were demonstrated in a cohort of 159 adult Fontan patients to be independently predictive of all-cause mortality, although correlated poorly with fibrosis severity on biopsy and features of portal hypertension.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Recent data from the Fontan Outcomes Study to Improve Transplant Experience and Results Registry suggested that no commonly used serological markers differentiated between those receiving an isolated heart vs combined heart and liver transplant, whereas clinical and imaging markers of cirrhosis or portal hypertension did.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> MELD-XI has been shown to correlate with the degree of biopsy-proven fibrosis in a case series of 70 stable Fontan patients.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Furthermore, it was predictive in another series of a composite cardiac endpoint of heart failure mortality, sudden death, and cardiac transplantation<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>, although its association with liver-related clinical outcomes was not evaluated. Our meta-regression did not identify a relationship between MELD-XI and liver outcomes, although the analysis was limited by only 8 studies reporting cirrhosis and MELD-XI. Noninvasive elastography techniques also are of questionable value in FALD due to the reliance on liver stiffness, which is elevated in hepatic congestion independently of the presence of fibrosis.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> Given the variability in the elastography techniques used (transient elastography, magnetic resonance elastography, and acoustic resonance force impulse imaging) as well as the cutoff values used for cirrhosis in the included studies, we were unable to quantitatively summarize the utility of elastography in FALD.</p><p id="p0105">Our study demonstrated a more than 2-fold higher diagnosis rate of cirrhosis by imaging than by biopsy. Hepatic imaging has traditionally been performed via ultrasound or computed tomography. However, liver parenchymal abnormalities, such as nodularity, are common and do not necessarily reflect histological advanced fibrosis or cirrhosis.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Magnetic resonance imaging has recently emerged as a more sensitive and reproducible imaging modality and has been shown to correlate with portal hypertension, liver biopsy, and clinical outcomes.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Biopsy remains the gold standard but is limited by procedural risks and the patchy nature of fibrosis in FALD, which can be missed in insufficient sampling.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Various biopsy scoring tools used in the included studies have focused on either periportal or sinusoidal fibrosis. It is likely that both processes occur in FALD and should be considered together in assessing liver disease.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref></p><p id="p0110">Various FALD risk factors have been inconsistently highlighted in existing literature. The current study-level meta-regression offers a more holistic overview, identifying time post-Fontan completion, AP Fontan, PCWP, and ventricular dysfunction to be significant predictors of cirrhosis. The lack of a subpulmonic ventricle post-Fontan completion exposes the liver to chronically elevated CVP, and over time, this results in congestive hepatopathy and cirrhosis. This is reflected in the latency for cirrhosis to manifest, with most patients diagnosed more than 10&#x000a0;years post-Fontan completion as noted in our study and previous large cohorts.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> This process may be accelerated by presence of ventricular dysfunction, as evidenced through elevated PCWP, also highlighted in our analyses. Consequently, there is increasing interest in modifiable risk factors and surrogate markers for early identification, risk stratification, and management. Importantly, right heart catheterization was done at different times between the included studies, with some around the time of cirrhosis diagnosis, which would diminish their value as predictors. In a cohort of over 1,000 Fontan patients who underwent routine catheterization at a median of 1&#x000a0;year post-Fontan, it was found that every 3&#x000a0;mm&#x000a0;Hg increase in CVP was associated with a 31% increased hazard of developing cirrhosis and HCC at long-term follow-up.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The current results also support the shift away from atriopulmonary Fontan, which has been demonstrated to have worse overall survival and increased risk of arrhythmias.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></p><p id="p0115">The presence of FALD is prognostic of liver and cardiac outcomes. As summarized in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>, several studies have described associations between FALD and overall survival. In the Fontan Outcomes Study to Improve Transplant Experience and Results Registry data, the authors found that isolated heart transplantation was noninferior to combined heart-liver transplantation in those with minimal clinical features of cirrhosis or portal hypertension at listing assessment. In contrast, in those with at least 2 features (imaging-proven cirrhosis, varices, splenomegaly, and recurrent ascites), combined heart-liver transplant was associated with better survival, suggesting the pretransplant liver disease to be a predictor of outcomes.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> As highlighted in our meta-analysis, HCC is a rare complication even at long-term follow-up. Once diagnosed, however, it does carry a dismal outcome with a 1-year survival of approximately 50%.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref> Interestingly, in North American, European, and Japanese cohorts, only half of patients with HCC had a preceding diagnosis of cirrhosis, much lower than non-Fontan patients with HCC.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Whether this represents different pathological processes contributing to carcinogenesis or an underdiagnosis of cirrhosis is unclear.</p><p id="p0120">With regard to management strategies, there is theoretical benefit in decreasing ventricular filling pressure, reducing pulmonary vascular resistance, or identifying and relieving anatomical obstructions. However, there have been limited studies in these domains with inconsistent outcomes.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> This may relate to small cohort sizes with short follow-up or selection of patients with irreversible liver disease, but importantly underscores the need for large prospective studies to better understand the mechanism of FALD in order to design more targeted therapies.</p><sec id="sec3.1"><title>Study limitations</title><p id="p0125">The results of the current study should be interpreted with caveats. Firstly, there is significant heterogeneity in outcomes. The current study, however, is not an attempt to offer a single definitive prevalence estimate. Rather, it recognizes and explores the underlying reason for such heterogeneity, which also exists in clinical practice, and offers potential reasons (eg, diagnostic method and risk factor profiles) that may help to stratify patients for FALD screening. Nevertheless, a more homogenous dataset would possess a higher internal validity, although this was not available for the current review. Secondly, many of the studies did not define HCC diagnosis or diagnosed HCC by imaging, which is not validated in a Fontan cohort. This may have overestimated the prevalence compared to if the diagnosis was histological only. Thirdly, data regarding risk factors for other forms of liver disease were rarely reported, and hence we were unable to control for the presence of coexisting primary liver disorders or lifestyle-related risk factors such as steatotic liver diseases. Finally, we did not quantitatively evaluate the prognostic significance of FALD on the basis of variations in analyzed variables and analysis methods between studies.</p></sec></sec><sec id="sec4"><title>Conclusions</title><p id="p0130">FALD is a highly heterogeneous syndrome that is common after Fontan completion. We have attempted to perform a comprehensive and unbiased meta-analysis of the prevalence and potential risk factors for FALD. More importantly, we have highlighted an inherent issue in the FALD literature, which is the need for large prospective studies with prognostic, validated, and homogenous definitions of liver disease in Fontan patients in order&#x000a0;to design better screening and preventative protocols.<boxed-text id="dtbox1"><label>Perspectives</label><p id="p0135"><bold>COMPETENCY IN MEDICAL KNOWLEDGE 1:</bold> FALD should be considered in all patients after 5 to 10&#x000a0;years post-Fontan completion. There is currently no single validated diagnostic test, so a multimodal approach, interpreted in the clinical context, should be adopted.</p><p id="p0140"><bold>COMPETENCY IN MEDICAL KNOWLEDGE 2:</bold> FALD is a prognostic marker of poor overall outcome and therefore should be considered in risk stratification of this unique group of patients.</p><p id="p0145"><bold>TRANSLATIONAL OUTLOOK 1:</bold> Diagnostic methods commonly applied to other causes of chronic liver disease may not be valid in FALD. As such, future research should aim to evaluate these and identify novel and prognostically meaningful markers of disease.</p></boxed-text></p></sec><sec sec-type="COI-statement" id="coi0010"><title>Funding support and author disclosures</title><p id="p0155">The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>d'Udekem</surname><given-names>Y.</given-names></name><name><surname>Iyengar</surname><given-names>A.J.</given-names></name><name><surname>Galati</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand</article-title><source>Circulation</source><volume>130</volume><year>2014</year><fpage>S32</fpage><lpage>S38</lpage><pub-id pub-id-type="pmid">25200053</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>C.J.</given-names></name><name><surname>Bradley</surname><given-names>E.A.</given-names></name><name><surname>Landzberg</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Fontan-associated liver disease: proceedings from the American college of cardiology stakeholders meeting, october 1 to 2, 2015, Washington DC</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>70</volume><issue>25</issue><year>2017</year><fpage>3173</fpage><lpage>3194</lpage><pub-id pub-id-type="pmid">29268929</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Stanton</surname><given-names>R.E.</given-names></name><name><surname>Lurie</surname><given-names>P.R.</given-names></name><name><surname>Lindesmith</surname><given-names>G.G.</given-names></name><name><surname>Meyer</surname><given-names>B.W.</given-names></name></person-group><article-title>The fontan procedure for tricuspid atresia</article-title><source>Circulation</source><volume>64</volume><year>1981</year><fpage>II140</fpage><lpage>II146</lpage><pub-id pub-id-type="pmid">7249315</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Alsaied</surname><given-names>T.</given-names></name><name><surname>Rathod</surname><given-names>R.H.</given-names></name><name><surname>Aboulhosn</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Reaching consensus for unified medical language in Fontan care</article-title><source>ESC Heart Fail</source><volume>8</volume><year>2021</year><fpage>3894</fpage><lpage>3905</lpage><pub-id pub-id-type="pmid">34190428</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Huh</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Imaging assessment of hepatic changes after fontan surgery: computed tomography, ultrasonography, and transient elastography</article-title><source>Int Heart J</source><volume>59</volume><issue>5</issue><year>2018</year><fpage>1008</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">30158375</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>D.J.</given-names></name><name><surname>Surrey</surname><given-names>L.F.</given-names></name><name><surname>Glatz</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Hepatic fibrosis is universal following fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>6</volume><year>2017</year><fpage>26</fpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Page</surname><given-names>M.J.</given-names></name><name><surname>McKenzie</surname><given-names>J.E.</given-names></name><name><surname>Bossuyt</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>Rev Esp Cardiol (Engl Ed</source><volume>74</volume><year>2021</year><fpage>790</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">34446261</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Inuzuka</surname><given-names>R.</given-names></name><name><surname>Nii</surname><given-names>M.</given-names></name><name><surname>Inai</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation</article-title><source>Heart</source><volume>109</volume><year>2022</year><fpage>276</fpage><lpage>282</lpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>T.</given-names></name></person-group><article-title>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</article-title><source>BMC Med Res Methodol</source><volume>14</volume><year>2014</year><fpage>135</fpage><pub-id pub-id-type="pmid">25524443</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name></person-group><article-title>Meta-analysis of proportions using generalized linear mixed models</article-title><source>Epidemiology</source><volume>31</volume><year>2020</year><fpage>713</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">32657954</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Zentner</surname><given-names>D.</given-names></name><name><surname>Phan</surname><given-names>K.</given-names></name><name><surname>Gorelik</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Fontan hepatopathy - managing unknowns</article-title><source>Heart Lung Circ</source><volume>32</volume><year>2023</year><fpage>535</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">36642589</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Glenn</surname><given-names>T.</given-names></name><name><surname>Duster</surname><given-names>N.</given-names></name><name><surname>Dwek</surname><given-names>J.</given-names></name><name><surname>Silva-Sepulveda</surname><given-names>J.</given-names></name><name><surname>El-Said</surname><given-names>H.G.</given-names></name></person-group><article-title>Selective use of pulmonary vasodilators in patients with fontan physiology</article-title><source>J&#x000a0;Interv Cardiol</source><volume>2022</volume><year>2022</year><object-id pub-id-type="publisher-id">7602793</object-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>D.S.</given-names></name><name><surname>Mao</surname><given-names>C.</given-names></name><name><surname>Mahle</surname><given-names>W.T.</given-names></name><etal/></person-group><article-title>Pretransplantation and post-transplantation liver disease assessment in adolescents undergoing isolated heart transplantation for fontan failure</article-title><source>J&#x000a0;Pediatr</source><volume>229</volume><year>2021</year><fpage>78</fpage><lpage>85.e2</lpage><pub-id pub-id-type="pmid">32976893</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Ybarra</surname><given-names>A.M.</given-names></name><name><surname>Khanna</surname><given-names>G.</given-names></name><name><surname>Turmelle</surname><given-names>Y.P.</given-names></name><etal/></person-group><article-title>Heterogeneous outcomes of liver disease after heart transplantation for a failed Fontan procedure</article-title><source>Pediatr Transpl</source><volume>25</volume><issue>8</issue><year>2021</year><object-id pub-id-type="publisher-id">e14094</object-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>J.S.</given-names></name><name><surname>Lee</surname><given-names>D.H.</given-names></name><name><surname>Cho</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Risk of liver cirrhosis and hepatocellular carcinoma after fontan operation: a need for surveillance</article-title><source>Cancers (Basel)</source><volume>12</volume><issue>7</issue><year>2020</year><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>I.</given-names></name><name><surname>Johnson</surname><given-names>J.</given-names></name><name><surname>Everitt</surname><given-names>M.D.</given-names></name><name><surname>Hoffman</surname><given-names>J.</given-names></name><name><surname>Yetman</surname><given-names>A.T.</given-names></name></person-group><article-title>Impact of liver disease after the fontan operation</article-title><source>Am J Cardiol</source><volume>115</volume><year>2015</year><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">25534765</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Pundi</surname><given-names>K.</given-names></name><name><surname>Pundi</surname><given-names>K.N.</given-names></name><name><surname>Kamath</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>Liver disease in patients after the fontan operation</article-title><source>Am J Cardiol</source><volume>117</volume><year>2016</year><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">26704027</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Martin de Miguel</surname><given-names>I.</given-names></name><name><surname>Kamath</surname><given-names>P.S.</given-names></name><name><surname>Egbe</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Haemodynamic and prognostic associations of liver fibrosis scores in Fontan-associated liver disease</article-title><source>Heart</source><volume>109</volume><year>2022</year><fpage>619</fpage><lpage>625</lpage></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>M.J.</given-names></name><name><surname>Reardon</surname><given-names>L.C.</given-names></name><name><surname>Aboulhosn</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical outcomes of adult fontan-associated liver disease and combined heart-liver transplantation</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>81</volume><year>2023</year><fpage>2149</fpage><lpage>2160</lpage><pub-id pub-id-type="pmid">37257950</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>W.N.</given-names></name><name><surname>Acherman</surname><given-names>R.J.</given-names></name><name><surname>Ciccolo</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>MELD-XI scores correlate with post-fontan hepatic biopsy fibrosis scores</article-title><source>Pediatr Cardiol</source><volume>37</volume><year>2016</year><fpage>1274</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">27300556</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Assenza</surname><given-names>G.E.</given-names></name><name><surname>Graham</surname><given-names>D.A.</given-names></name><name><surname>Landzberg</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery</article-title><source>Heart</source><volume>99</volume><year>2013</year><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">23406689</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>M.</given-names></name><name><surname>Mudaliar</surname><given-names>S.</given-names></name><name><surname>Prince</surname><given-names>D.</given-names></name><name><surname>Than</surname><given-names>N.N.</given-names></name><name><surname>Cordina</surname><given-names>R.</given-names></name><name><surname>Majumdar</surname><given-names>A.</given-names></name></person-group><article-title>Poor correlation of 2D shear wave elastography and transient elastography in Fontan-associated liver disease: a head-to-head comparison</article-title><source>JGH Open</source><volume>7</volume><year>2023</year><fpage>690</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">37908293</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Poterucha</surname><given-names>J.T.</given-names></name><name><surname>Johnson</surname><given-names>J.N.</given-names></name><name><surname>Qureshi</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Magnetic resonance elastography: a novel technique for the detection of hepatic fibrosis and hepatocellular carcinoma after the fontan operation</article-title><source>Mayo Clin Proc</source><volume>90</volume><year>2015</year><fpage>882</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">26059757</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Alsaied</surname><given-names>T.</given-names></name><name><surname>Possner</surname><given-names>M.</given-names></name><name><surname>Lubert</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Relation of magnetic resonance elastography to fontan failure and portal hypertension</article-title><source>Am J Cardiol</source><volume>124</volume><year>2019</year><fpage>1454</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">31474329</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.M.</given-names></name><name><surname>Jonas</surname><given-names>M.M.</given-names></name><name><surname>Opotowsky</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Portal and centrilobular hepatic fibrosis in Fontan circulation and clinical outcomes</article-title><source>J&#x000a0;Heart Lung Transpl</source><volume>34</volume><year>2015</year><fpage>883</fpage><lpage>891</lpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M.C.</given-names></name><name><surname>Sullivan</surname><given-names>L.M.</given-names></name><name><surname>Glatz</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery</article-title><source>Pediatr Cardiol</source><volume>34</volume><year>2013</year><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">22695765</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>W.N.</given-names></name><name><surname>Winn</surname><given-names>B.J.</given-names></name><name><surname>Yumiaco</surname><given-names>N.S.</given-names></name><etal/></person-group><article-title>Transvenous hepatic biopsy in stable Fontan patients undergoing cardiac catheterization</article-title><source>Pediatr Cardiol</source><volume>35</volume><year>2014</year><fpage>1273</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">24817681</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Ohuchi</surname><given-names>H.</given-names></name><name><surname>Hayama</surname><given-names>Y.</given-names></name><name><surname>Nakajima</surname><given-names>K.</given-names></name><name><surname>Kurosaki</surname><given-names>K.</given-names></name><name><surname>Shiraishi</surname><given-names>I.</given-names></name><name><surname>Nakai</surname><given-names>M.</given-names></name></person-group><article-title>Incidence, predictors, and mortality in patients with liver cancer after fontan operation</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>10</volume><year>2021</year><object-id pub-id-type="publisher-id">e016617</object-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Egbe</surname><given-names>A.C.</given-names></name><name><surname>Poterucha</surname><given-names>J.T.</given-names></name><name><surname>Warnes</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma after fontan operation: multicenter case series</article-title><source>Circulation</source><volume>138</volume><year>2018</year><fpage>746</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">30359134</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Nii</surname><given-names>M.</given-names></name><name><surname>Inuzuka</surname><given-names>R.</given-names></name><name><surname>Inai</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Incidence and expected probability of liver cirrhosis and hepatocellular carcinoma after fontan operation</article-title><source>Circulation</source><volume>144</volume><year>2021</year><fpage>2043</fpage><lpage>2045</lpage><pub-id pub-id-type="pmid">34928702</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Possner</surname><given-names>M.</given-names></name><name><surname>Gordon-Walker</surname><given-names>T.</given-names></name><name><surname>Egbe</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma and the Fontan circulation: clinical presentation and outcomes</article-title><source>Int J Cardiol</source><volume>322</volume><year>2021</year><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">32828959</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>A.</given-names></name><name><surname>Sandhu</surname><given-names>S.</given-names></name><name><surname>Lai</surname><given-names>J.P.</given-names></name><name><surname>Sandhu</surname><given-names>D.S.</given-names></name></person-group><article-title>Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review</article-title><source>World J Hepatol</source><volume>11</volume><year>2019</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">30705715</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Zafar</surname><given-names>F.</given-names></name><name><surname>Lubert</surname><given-names>A.M.</given-names></name><name><surname>Trout</surname><given-names>A.T.</given-names></name><etal/></person-group><article-title>Abdominal CT and MRI findings of portal hypertension in children and adults with fontan circulation</article-title><source>Radiology</source><volume>303</volume><year>2022</year><fpage>557</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">35289663</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Gunsaulus</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Haack</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Cardiac MRI-derived inferior vena cava cross-sectional area correlates with measures of fontan-associated liver disease</article-title><source>Pediatr Cardiol</source><volume>45</volume><year>2022</year><fpage>909</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">36454265</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Thrane</surname><given-names>K.J.</given-names></name><name><surname>Muller</surname><given-names>L.S.O.</given-names></name><name><surname>Suther</surname><given-names>K.R.</given-names></name><etal/></person-group><article-title>Spectrum of Fontan-associated liver disease assessed by MRI and US in young adolescents</article-title><source>Abdom Radiol</source><volume>46</volume><year>2021</year><fpage>3205</fpage><lpage>3216</lpage></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>Y.R.</given-names></name><name><surname>Kim</surname><given-names>S.U.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation</article-title><source>J&#x000a0;Thorac Cardiovasc Surg</source><volume>164</volume><year>2021</year><fpage>1176</fpage><lpage>1185.e3</lpage><pub-id pub-id-type="pmid">35034765</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Sakamori</surname><given-names>R.</given-names></name><name><surname>Yamada</surname><given-names>R.</given-names></name><name><surname>Tahata</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery</article-title><source>J Gastroenterol</source><volume>57</volume><year>2022</year><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">35064829</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Navallas</surname><given-names>M.</given-names></name><name><surname>Yoo</surname><given-names>S.J.</given-names></name><name><surname>Chavhan</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>Semiquantitative characterization of dynamic magnetic resonance perfusion of the liver in pediatric Fontan patients</article-title><source>Pediatr Radiol</source><volume>52</volume><year>2021</year><fpage>483</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">34854967</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Martinez-Quintana</surname><given-names>E.</given-names></name><name><surname>Rodriguez-Gonzalez</surname><given-names>F.</given-names></name></person-group><article-title>Blood test assessment of liver ultrasound findings in patients with fontan surgery</article-title><source>Am J Cardiovasc Dis</source><volume>11</volume><issue>5</issue><year>2021</year><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">34849292</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Langguth</surname><given-names>P.</given-names></name><name><surname>Salehi Ravesh</surname><given-names>M.</given-names></name><name><surname>Moritz</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Non-contrast enhanced magnetic resonance imaging for characterization of Fontan associated liver disease</article-title><source>Int J Cardiol</source><volume>349</volume><year>2021</year><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">34808211</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J.H.</given-names></name><name><surname>Khodami</surname><given-names>J.K.</given-names></name><name><surname>Moritz</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Surveillance of fontan associated liver disease in childhood and adolescence</article-title><source>Semin Thorac Cardiovasc Surg</source><volume>34</volume><year>2021</year><fpage>642</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">33979666</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Emamaullee</surname><given-names>J.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Weaver</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Non-invasive biomarkers of Fontan-associated liver disease</article-title><source>JHEP Rep</source><volume>3</volume><year>2021</year><object-id pub-id-type="publisher-id">100362</object-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>De Bruyne</surname><given-names>R.</given-names></name><name><surname>Vandekerckhove</surname><given-names>K.</given-names></name><name><surname>Van Overschelde</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Non-invasive assessment of liver abnormalities in pediatric Fontan patients</article-title><source>Eur J Pediatr</source><volume>181</volume><year>2021</year><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">34231051</pub-id>
</element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Chemello</surname><given-names>L.</given-names></name><name><surname>Padalino</surname><given-names>M.</given-names></name><name><surname>Zanon</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction</article-title><source>J&#x000a0;Cardiovasc Development Dis</source><volume>8</volume><issue>10</issue><year>2021</year><fpage>117</fpage></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Anigwe</surname><given-names>C.</given-names></name><name><surname>Yogeswaran</surname><given-names>V.</given-names></name><name><surname>Moon-Grady</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Outcomes among adult survivors of total cavopulmonary Fontan palliation for single ventricle</article-title><source>Heart</source><volume>108</volume><year>2021</year><fpage>1209</fpage><lpage>1215</lpage></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>D.</given-names></name><name><surname>Grewal</surname><given-names>J.</given-names></name><name><surname>Barlow</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Atrial arrhythmias and thromboembolic complications in adults post Fontan surgery</article-title><source>Open Heart</source><volume>7</volume><year>2020</year><fpage>10</fpage></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Tellez</surname><given-names>L.</given-names></name><name><surname>Rodriguez de Santiago</surname><given-names>E.</given-names></name><name><surname>Minguez</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: the VALDIG Fonliver prospective cohort</article-title><source>J&#x000a0;Hepatol</source><volume>72</volume><year>2020</year><fpage>702</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">31726116</pub-id>
</element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Sethasathien</surname><given-names>S.</given-names></name><name><surname>Silvilairat</surname><given-names>S.</given-names></name><name><surname>Sittiwangkul</surname><given-names>R.</given-names></name><name><surname>Makonkawkeyoon</surname><given-names>K.</given-names></name><name><surname>Pongprot</surname><given-names>Y.</given-names></name></person-group><article-title>Associated factors of liver disease after fontan operation in relation to ultrasound liver elastography</article-title><source>Pediatr Cardiol</source><volume>41</volume><year>2020</year><fpage>1639</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">32740670</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>B.E.</given-names></name><name><surname>Yang</surname><given-names>H.K.</given-names></name><name><surname>Doyle</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Cardiovascular and abdominal flow alterations in adults with morphologic evidence of liver disease post Fontan palliation</article-title><source>Int J Cardiol</source><volume>317</volume><year>2020</year><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">32470536</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>SmasSuska</surname><given-names>M.</given-names></name><name><surname>Skubera</surname><given-names>M.</given-names></name><name><surname>Wilkosz</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Noninvasive assessment of liver status in adult patients after the Fontan procedure</article-title><source>Pol Arch Intern Med</source><volume>129</volume><issue>3</issue><year>2019</year><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">30778020</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Silva-Sepulveda</surname><given-names>J.A.</given-names></name><name><surname>Fonseca</surname><given-names>Y.</given-names></name><name><surname>Vodkin</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Evaluation of Fontan liver disease: correlation of transjugular liver biopsy with magnetic resonance and hemodynamics</article-title><source>Congenit</source><volume>14</volume><year>2019</year><fpage>600</fpage><lpage>608</lpage></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Munsterman</surname><given-names>I.D.</given-names></name><name><surname>Duijnhouwer</surname><given-names>A.L.</given-names></name><name><surname>Kendall</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort</article-title><source>Eur Heart J</source><volume>40</volume><year>2019</year><fpage>1057</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">30346512</pub-id>
</element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>T.G.</given-names></name><name><surname>Iyengar</surname><given-names>A.J.</given-names></name><name><surname>Hardikar</surname><given-names>W.</given-names></name><name><surname>Sood</surname><given-names>S.</given-names></name><name><surname>d'Udekem</surname><given-names>Y.</given-names></name></person-group><article-title>Prevalence of hepatocellular carcinoma in the entire Fontan population of Australia and New Zealand</article-title><source>JTCVS Tech</source><volume>2</volume><year>2020</year><fpage>128</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">34317777</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Schachter</surname><given-names>J.L.</given-names></name><name><surname>Patel</surname><given-names>M.</given-names></name><name><surname>Horton</surname><given-names>S.R.</given-names></name><name><surname>Mike Devane</surname><given-names>A.</given-names></name><name><surname>Ewing</surname><given-names>A.</given-names></name><name><surname>Abrams</surname><given-names>G.A.</given-names></name></person-group><article-title>FibroSURE and elastography poorly predict the severity of liver fibrosis in Fontan-associated liver disease</article-title><source>Congenit</source><volume>13</volume><year>2018</year><fpage>764</fpage><lpage>770</lpage></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Nandwana</surname><given-names>S.B.</given-names></name><name><surname>Olaiya</surname><given-names>B.</given-names></name><name><surname>Cox</surname><given-names>K.</given-names></name><name><surname>Sahu</surname><given-names>A.</given-names></name><name><surname>Mittal</surname><given-names>P.</given-names></name></person-group><article-title>Abdominal imaging surveillance in adult patients after Fontan procedure: risk of chronic liver disease and hepatocellular carcinoma</article-title><source>Curr Probl Diagn Radiol</source><volume>47</volume><year>2018</year><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">28602501</pub-id>
</element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.O.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Jang</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Hepatic stiffness using shear wave elastography and the related factors for a fontan circulation</article-title><source>Pediatr Cardiol</source><volume>39</volume><year>2018</year><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">28932977</pub-id>
</element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Egbe</surname><given-names>A.C.</given-names></name><name><surname>Reddy</surname><given-names>Y.N.V.</given-names></name><name><surname>Khan</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Venous congestion and pulmonary vascular function in Fontan circulation: implications for prognosis and treatment</article-title><source>Int J Cardiol</source><volume>271</volume><year>2018</year><fpage>312</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">30223363</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Buendia-Fuentes</surname><given-names>F.</given-names></name><name><surname>Melero-Ferrer</surname><given-names>J.L.</given-names></name><name><surname>Plaza-Lopez</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Noninvasive liver assessment in adult patients with fontan circulation using acoustic radiation force impulse elastography and hepatic magnetic resonance imaging</article-title><source>World J Pediatr Congenit Heart Surg</source><volume>9</volume><year>2018</year><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">29103357</pub-id>
</element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Surrey</surname><given-names>L.F.</given-names></name><name><surname>Russo</surname><given-names>P.</given-names></name><name><surname>Rychik</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Prevalence and characterization of fibrosis in surveillance liver biopsies of patients with Fontan circulation</article-title><source>Hum Pathol</source><volume>57</volume><year>2016</year><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">27476041</pub-id>
</element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Agnoletti</surname><given-names>G.</given-names></name><name><surname>Ferraro</surname><given-names>G.</given-names></name><name><surname>Bordese</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Fontan circulation causes early, severe liver damage. Should we offer patients a tailored strategy?</article-title><source>Int J Cardiol</source><volume>209</volume><year>2016</year><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">26882184</pub-id>
</element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Wallihan</surname><given-names>D.B.</given-names></name><name><surname>Podberesky</surname><given-names>D.J.</given-names></name><name><surname>Marino</surname><given-names>B.S.</given-names></name><name><surname>Sticka</surname><given-names>J.S.</given-names></name><name><surname>Serai</surname><given-names>S.</given-names></name></person-group><article-title>Relationship of MR elastography determined liver stiffness with cardiac function after Fontan palliation</article-title><source>J Magn Reson Imaging</source><volume>40</volume><year>2014</year><fpage>1328</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">24408379</pub-id>
</element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Elder</surname><given-names>R.W.</given-names></name><name><surname>McCabe</surname><given-names>N.M.</given-names></name><name><surname>Hebson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study</article-title><source>Int J Cardiol</source><volume>168</volume><year>2013</year><fpage>3764</fpage><lpage>3769</lpage><pub-id pub-id-type="pmid">23849105</pub-id>
</element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Sakamori</surname><given-names>R.</given-names></name><name><surname>Yamada</surname><given-names>R.</given-names></name><name><surname>Tahata</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery</article-title><source>J&#x000a0;Gastroenterol</source><volume>57</volume><year>2022</year><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">35064829</pub-id>
</element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>T.G.</given-names></name><name><surname>Iyengar</surname><given-names>A.J.</given-names></name><name><surname>Hardikar</surname><given-names>W.</given-names></name><name><surname>Sood</surname><given-names>S.</given-names></name><name><surname>d'Udekem</surname><given-names>Y.</given-names></name></person-group><article-title>Prevalence of hepatocellular carcinoma in the entire Fontan population of Australia and New Zealand</article-title><source>JTCVS Tech</source><volume>2</volume><year>2020</year><fpage>128</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">34317777</pub-id>
</element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Wallihan</surname><given-names>D.B.</given-names></name><name><surname>Podberesky</surname><given-names>D.J.</given-names></name><name><surname>Marino</surname><given-names>B.S.</given-names></name><name><surname>Sticka</surname><given-names>J.S.</given-names></name><name><surname>Serai</surname><given-names>S.</given-names></name></person-group><article-title>Relationship of MR elastography determined liver stiffness with cardiac function after Fontan palliation</article-title><source>J&#x000a0;Magn Reson Imaging</source><volume>40</volume><year>2014</year><fpage>1328</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">24408379</pub-id>
</element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Najashi</surname><given-names>K.A.</given-names></name><name><surname>Najashi</surname><given-names>N.A.</given-names></name><name><surname>Ahmed</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The prognostic role of liver volumetry in Fontan patients</article-title><source>Cardiol Young</source><volume>33</volume><year>2022</year><fpage>1834</fpage><lpage>1839</lpage><pub-id pub-id-type="pmid">36258282</pub-id>
</element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Brayer</surname><given-names>S.W.</given-names></name><name><surname>Zafar</surname><given-names>F.</given-names></name><name><surname>Lubert</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Relation of magnetic resonance elastography to fontan circulatory failure in a cohort of pediatric and adult patients</article-title><source>Pediatr Cardiol</source><volume>42</volume><year>2021</year><fpage>1871</fpage><lpage>1878</lpage><pub-id pub-id-type="pmid">34448042</pub-id>
</element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Alsaied</surname><given-names>T.</given-names></name><name><surname>Possner</surname><given-names>M.</given-names></name><name><surname>Lubert</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Thromboembolic events are independently associated with liver stiffness in patients with fontan circulation</article-title><source>J&#x000a0;Clin Med</source><volume>9</volume><issue>2</issue><year>2020</year><fpage>418</fpage><pub-id pub-id-type="pmid">32032996</pub-id>
</element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Lubert</surname><given-names>A.M.</given-names></name><name><surname>Opotowsky</surname><given-names>A.R.</given-names></name><name><surname>Palermo</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Relation of liver volume to adverse cardiovascular events in adolescents and adults with fontan circulation</article-title><source>Am J Cardiol</source><volume>165</volume><year>2021</year><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">34893302</pub-id>
</element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>W.N.</given-names></name><name><surname>Acherman</surname><given-names>R.J.</given-names></name><name><surname>Reardon</surname><given-names>L.C.</given-names></name><etal/></person-group><article-title>Fontan outcomes and pulmonary blood flow at birth</article-title><source>Pediatr Cardiol</source><volume>37</volume><year>2016</year><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">26187516</pub-id>
</element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>W.R.</given-names></name><name><surname>Borlaug</surname><given-names>B.A.</given-names></name><name><surname>Hagler</surname><given-names>D.J.</given-names></name><name><surname>Connolly</surname><given-names>H.M.</given-names></name><name><surname>Egbe</surname><given-names>A.C.</given-names></name></person-group><article-title>Haemodynamic profiles in adult Fontan patients: associated haemodynamics and prognosis</article-title><source>Eur J Heart Fail</source><volume>21</volume><year>2019</year><fpage>803</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">30672076</pub-id>
</element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Sagawa</surname><given-names>T.</given-names></name><name><surname>Kogiso</surname><given-names>T.</given-names></name><name><surname>Sugiyama</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>E.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Tokushige</surname><given-names>K.</given-names></name></person-group><article-title>Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease</article-title><source>Hepatol</source><volume>50</volume><issue>7</issue><year>2020</year><fpage>853</fpage><lpage>862</lpage></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0160">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplemental_Material</title></caption><media xlink:href="mmc1.docx"/></supplementary-material>
</p></sec><fn-group><fn id="d36e1803"><p id="ntpara0015aa">The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors&#x02019; institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the <ext-link ext-link-type="uri" xlink:href="https://www.jacc.org/author-center" id="interref1">Author Center</ext-link>.</p></fn><fn id="appsec2"><p>Appendix</p><p id="p0165">For the search strategy as well as supplemental tables and figures, please see the online version of this paper.</p></fn></fn-group></back></article>